- Home
- GILD vs MU Comparison
GILD vs MU Comparison
Compare GILD & MU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | MU |
|---|---|---|
| Founded | 1987 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4B | 444.2B |
| IPO Year | 2000 | 1994 |
Fundamental Metrics
Financial Performance| Metric | GILD | MU |
|---|---|---|
| Price | $144.37 | $424.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 31 |
| Target Price | $146.50 | ★ $361.52 |
| AVG Volume (30 Days) | 5.5M | ★ 23.3M |
| Earning Date | 01-01-0001 | 03-17-2026 |
| Dividend Yield | ★ 2.26% | 0.11% |
| EPS Growth | ★ 1684.21 | 984.29 |
| EPS | ★ 6.78 | 4.60 |
| Revenue | $24,689,000,000.00 | ★ $30,391,000,000.00 |
| Revenue This Year | $4.68 | $112.37 |
| Revenue Next Year | $6.10 | $30.09 |
| P/E Ratio | ★ $21.44 | $88.02 |
| Revenue Growth | 9.98 | ★ 49.55 |
| 52 Week Low | $95.30 | $61.54 |
| 52 Week High | $157.29 | $455.50 |
Technical Indicators
Market Signals| Indicator | GILD | MU |
|---|---|---|
| Relative Strength Index (RSI) | 48.65 | 57.21 |
| Support Level | $142.93 | $363.90 |
| Resistance Level | $157.29 | $443.72 |
| Average True Range (ATR) | 3.21 | 18.88 |
| MACD | -1.06 | -0.84 |
| Stochastic Oscillator | 27.44 | 83.76 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About MU Micron Technology Inc.
Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.